Predicting ovarian cancer prognosis and immunotherapy response through siglec15 and PD-L1 expression analysis
Our findings emphasize the importance of combining assessment of Siglec15 and PD-L1 expression in patient stratification and treatment decision-making for OC, particularly regarding immunotherapy.
Authors
- Tianwen Xu (ORCID: https://orcid.org/0000-0003-2519-8140)
- Shiyin Hu (ORCID: https://orcid.org/0000-0003-4602-6970)
- Peiru Zhang (ORCID: https://orcid.org/0000-0002-5896-8511)
- Yanru Qiu
- Aiyue Zhao
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- Second Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-10-11
- DOI
- https://doi.org/10.1016/j.tranon.2025.102563
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00